gilteritinib and Bone-Marrow-Neoplasms

gilteritinib has been researched along with Bone-Marrow-Neoplasms* in 1 studies

Other Studies

1 other study(ies) available for gilteritinib and Bone-Marrow-Neoplasms

Article	Year
A case report of combined treatment of gilteritinib and LH-RH agonist for Fms-related tyrosine kinase 3 receptor mutation-positive acute myeloid leukemia and bone marrow metastasis of prostate cancer. Annals of hematology, 2022, Volume: 101, Issue:2 Topics: Aniline Compounds; Bone Marrow Neoplasms; fms-Like Tyrosine Kinase 3; Gonadotropin-Releasing Hormone; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Oligopeptides; Prostatic Neoplasms; Pyrazines	2022

Article

Year

A case report of combined treatment of gilteritinib and LH-RH agonist for Fms-related tyrosine kinase 3 receptor mutation-positive acute myeloid leukemia and bone marrow metastasis of prostate cancer.

Annals of hematology, 2022, Volume: 101, Issue:2

Topics: Aniline Compounds; Bone Marrow Neoplasms; fms-Like Tyrosine Kinase 3; Gonadotropin-Releasing Hormone; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Oligopeptides; Prostatic Neoplasms; Pyrazines

2022